The product line designated as finerenone and sivelestat sodium pharma-grade API intermediates is supplied for conversion into oral solid-dose and injectable finished products. Finerenone, a nonsteroidal mineralocorticoid receptor antagonist, is identified by CAS Registry Number 1050477-31-0, molecular formula C₂₁H₂₂N₄O₃, and molecular mass 378.43 g/mol. Sivelestat sodium is handled as the hydrate form, described as N-[2-[[[4-(2,2-dimethylpropanoyloxy)phenyl]sulfonyl]amino]benzoyl]glycine sodium salt tetrahydrate, with molecular mass 528.51 g/mol for the tetrahydrate and 456.45 g/mol for the anhydrous sodium salt, CAS Registry Number 201677-61-4. Oral-grade finerenone intermediate is used for tablet and capsule development at final label strengths of 10 mg and 20 mg; the injectable-grade sivelestat sodium intermediate is processed into lyophilized or solution dosage forms for intravenous infusion after reconstitution and dilution.

Manufacturer-assigned model identifiers follow a format such as FIN-INT-04 for the finerenone penultimate intermediate and SIV-API-01 for the sivelestat sodium active stream. These identifiers are internal grade codes, not pharmacopeial designations; they link each lot to the route of synthesis, crystallization solvent system, and intended route of administration. The oral finerenone stream is not interchangeable with the injectable sivelestat stream because the two materials have different residual solvent profiles, endotoxin controls, and particle-size targets. Batch records are controlled under ICH Q7, and change-over cleaning between the two product classes is validated by swab sampling with acceptance limits derived from health-based exposure data.

A representative specification matrix is shown below; final acceptance values are dose-specific and filing-specific.

Residual solvent control in the finerenone stream is complicated by the presence of polar aprotic solvents that can form solvates with the final crystal. When high-temperature vacuum drying is tightened to remove N,N-dimethylformamide below its ICH Q3C class 2 limit of 880 ppm, the crystal habit can shift if the dryer wall temperature exceeds the desolvation onset of the intermediate. Production-scale agitated vacuum dryers with programmable step ramps are therefore preferred over static tray dryers, and batch logging includes jacket temperature, vacuum level, and condenser load. Milling after drying can increase amorphous content; if the amorphous fraction is too high, compressibility and chemical stability may change. For this reason, X-ray powder diffraction and differential scanning calorimetry are used to detect form change after micronization, and nitrogen-fed spiral jet mills are operated with classifier speed setpoints that maintain the target particle-size distribution without uncontrolled overheating.

What Distinguishes Finerenone Intermediates from Spironolactone and Eplerenone Intermediates?

Finerenone belongs to the dihydronaphthyridine class, and its synthesis proceeds through a chiral 4-aryl-1,4-dihydropyridine-type intermediate rather than through a steroidal scaffold. As a result, the impurity profile of the intermediate does not include phytosterol-derived oxidation products that are monitored in spironolactone or eplerenone streams. The absence of the steroidal core changes crystallization solvent selection; finerenone intermediates are typically isolated from alcohol/water or ester/alkane systems, while steroidal intermediates often require ketone or chlorinated-solvent recrystallization. This structural difference is operationally significant because the finerenone stream can be dried without removing and recovering chlorinated solvents, and the residual solvent schedule is dominated by class 2 and class 3 solvents rather than class 1 chloro-alkanes.

Compared with eplerenone, the finerenone intermediate has a lower molecular mass and a higher dose-normalized content-uniformity challenge because the finished tablet may contain only 10 mg or 20 mg of active in a core weight above 100 mg. In low-dose blends, segregation of the API from larger excipient particles can cause assay variability. Formulators therefore prepare a pre-blend of finerenone with a portion of microcrystalline cellulose or lactose monohydrate and pass the blend through a 0.5 mm or 1.0 mm screen before final mixing. Blend uniformity is tested using stratified sampling at the intended compression speeds and compared with the acceptance criteria of USP <905>. Published data for finerenone-specific blend segregation at commercial compression speeds is limited; process development studies are required to establish the maximum blender load and the minimum number of revolutions.

Sivelestat Sodium Hydrate Handling in Injectable Formulation Trains

The injectable-grade sivelestat sodium stream is a low-molecular-weight synthetic neutrophil elastase inhibitor. Unlike protein-based elastase inhibitors, sivelestat sodium does not require viral inactivation or removal steps, and it presents no aggregate or subvisible-particle profile derived from tertiary structure. The main injectable-processing risks are hydrolysis of the ester moiety in aqueous solution, pH drift during reconstitution, and endotoxin introduction from water-for-injection or packaging components. Therefore, the API is dissolved in cold water-for-injection, the solution is sterile-filtered through 0.22 µm membrane filters, and the filtrate is held in stainless-steel vessels validated for bioburden control before filling. When lyophilization is specified, the fill solution is cooled below its collapse temperature and dried under vacuum; the cake appearance and reconstitution time are monitored as release and stability parameters.

Sivelestat sodium differs from other small-molecule elastase inhibitors in its solubility and ionizable sodium salt form. The presence of the sodium salt improves dissolution but also raises the need for sodium ion identification and control of counterion ratio. In lyophilized cakes, residual moisture is controlled by Karl Fischer titration; a typical target for freeze-dried parenterals is not more than 1.0% to 3.0% water, but the specific value must maintain cake integrity and minimize hydrolysis. Sterile API or sterile-filterable solution is delivered under cleanroom grade A conditions, with sterility assurance based on terminal filtration rather than terminal steam sterilization because the ester functionality is thermally labile. The sterilizing-grade filter must be integrity tested before and after filtration by bubble point or pressure decay according to filter manufacturer instructions; filter compatibility with sivelestat sodium solution is confirmed by a static soak study because the ester bond can hydrolyze if the pH deviates and may generate free acid or degradation products.

When the same oral finerenone intermediate is assigned to wet granulation, the granulation water activity becomes a critical process parameter. Excess water can plasticize the amorphous fraction generated during earlier micronization and can lower the glass transition of the blend, leading to sticky granulation that overloads the mill and reduces tablet tensile strength. A wet granulation process for low-dose finerenone therefore uses a binder solution of hypromellose or povidone at a defined solid content, but the water spray rate is set so that the end-of-granulation moisture is below the threshold at which powder-bed torque begins to rise. Drying in a fluid-bed dryer is preferred because it removes surface moisture rapidly and limits the time at elevated relative humidity. Loss on drying by infrared balance or Karl Fischer is measured at the start of the drying curve, at the predicted endpoint, and after a defined equilibration time in the granulator room.

For dry granulation, roller compaction of the finerenone blend is used to avoid water exposure entirely. The intermediate is blended with intragranular excipients, compacted with a defined roll pressure and gap, then milled to produce granules with a target particle-size distribution. Ribbon density is monitored because over-densification can reduce tablet disintegration and dissolution. Dissolution testing is performed according to USP <711> with an apparatus and medium defined for the specific formulation; the finerenone intermediate itself does not carry a dissolution specification, but the granule and tablet intermediates are tested for particle size and bulk density.

When Residual-Solvent Limits for Class 1 and Class 2 Mixtures Compress the Drying Window

Residual solvent removal from the two intermediate classes is not a single-endpoint operation. The finerenone intermediate may retain methanol, ethanol, or polar aprotic solvents, while the sivelestat sodium hydrate may retain ethanol or acetone from the final crystallization and washing sequence. If a class 1 solvent is used upstream, the final isolation must demonstrate that benzene is below 2 ppm, carbon tetrachloride below 4 ppm, and 1,2-dichloroethane below 5 ppm. These limits are applied under ICH Q3C and are non-negotiable in the final API because they are based on toxicological safety rather than process convenience. Where a mixed solvent system is used, the drying window narrows because the more volatile solvent may be removed first while the higher-boiling solvent remains in the crystal lattice; unbalanced drying can produce a lot that passes the total solvent limit but fails a specific solvent residue criterion.

Elemental impurity control follows ICH Q3D. The finerenone intermediate may contain palladium or nickel residues if a transition-metal-catalyzed coupling step is used; these are reduced by recrystallization, scavenger treatment, or activated-carbon filtration before final isolation. The analytical method is inductively coupled plasma mass spectrometry or optical emission spectrometry, and the limit is expressed as micrograms per day based on the intended oral dose. Published data for the exact palladium concentration in finerenone final API is limited; the value is established from process capability studies and batch history. The sivelestat sodium injectable stream is handled with a stricter emphasis on chromium, iron, and zinc because these elements can leach from stainless-steel processing equipment during solution hold steps; passivation and rinse-water monitoring are part of the release program.

X-ray powder diffraction is used for form identification of the finerenone intermediate. If the diffractogram shows a shift in the 2θ region associated with the crystalline lattice, the batch is quarantined and reexamined by differential scanning calorimetry. Published data for finerenone polymorph transition temperatures is limited; the manufacturing site therefore establishes an internal form library from representative lots and uses it for release. For sivelestat sodium hydrate, the hydration state is verified by Karl Fischer titration and by thermogravimetric analysis because dehydration alters stoichiometry and can affect reconstitution.

Long-term stability studies of intermediates are conducted in climate chambers at 25 °C/60% RH and 40 °C/75% RH according to ICH Q1A. For sivelestat sodium hydrate, storage above 25 °C may require protection from moisture to avoid deliquescence or hydrate redistribution. Published data for this specific stream's humidity threshold is limited; each container is qualified with high-density polyethylene bags and desiccant where needed. Bulk density and tapped density are measured according to USP <616>, and the acceptable range is determined by the target capsule filling or tablet compression performance rather than by a universal pharmacopeial limit.